Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium–Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials
Why the study?
Although SGLT2 inhibitors improve health status in heart failure, whether these benefits are similar across races was not established.
Does SGLT2 inhibitor therapy improve health status similarly in Black compared with White patients with heart failure?
Population
935 self-identified Black and White patients with heart failure across 3 US randomized trials
Comparison
SGLT2 inhibitors vs placebo
Design
Patient-level meta-analysis of 3 randomized clinical trials
Follow-up
12 weeks
Authors
Discussion
Loading...
Member takes
Implication
SGLT2 inhibitors improve health status similarly across races in heart failure; confirms consistent benefit without interaction in meta-analysis.
Structured PICO
Does SGLT2 inhibitor therapy improve health status similarly in Black compared with White patients with heart failure?
P
Population
935 self-identified Black and White patients with heart failure from 3 United States-based RCTs (DEFINE-HF, PRESERVED-HF, CHIEF-HF)
I
Intervention
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) for 12 weeks
C
Comparator
Placebo
O
Outcome
12-week change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary scorepatient reported
SGLT2 inhibitors provide consistent and significant improvements in health-related quality of life for both Black and White patients with heart failure.
Cite This Study
Gupta et al. (2023) studied this question.